Cited 0 times in
FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤영섭 | - |
dc.contributor.author | 이지윤 | - |
dc.date.accessioned | 2024-02-15T06:50:34Z | - |
dc.date.available | 2024-02-15T06:50:34Z | - |
dc.date.issued | 2023-11 | - |
dc.identifier.issn | 0390-6078 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198055 | - |
dc.description.abstract | Treating patients with refractory acute myeloid leukemia (AML) remains challenging. Currently there is no effective treatment for refractory AML. Increasing evidence has demonstrated that refractory/relapsed AML is associated with leukemic blasts which can confer resistance to anticancer drugs. We have previously reported that high expression of Fms-related tyrosine kinase 4 (FLT4) is associated with increased cancer activity in AML. However, the functional role of FLT4 in leukemic blasts remains unknown. Here, we explored the significance of FLT4 expression in leukemic blasts of refractory patients and mechanisms involved in the survival of AML blasts. Inhibition or absence of FLT4 in AML blasts suppressed homing to bone marrow of immunocompromised mice and blocked engraftment of AML blasts. Moreover, FLT4 inhibition by MAZ51, an antagonist, effectively reduced the number of leukemic cell-derived colony-forming units and increased apoptosis of blasts derived from refractory patients when it was co-treated with cytosine arabinoside under vascular endothelial growth factor C, its ligand. AML patients who expressed high cytosolic FLT4 were linked to an AML-refractory status by internalization mechanism. In conclusion, FLT4 has a biological function in leukemogenesis and refractoriness. This novel insight will be useful for targeted therapy and prognostic stratification of AML. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | Italian, English | - |
dc.publisher | Ferrata Storti Foundation | - |
dc.relation.isPartOf | HAEMATOLOGICA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antineoplastic Agents* / therapeutic use | - |
dc.subject.MESH | Bone Marrow / metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leukemia, Myeloid, Acute* / diagnosis | - |
dc.subject.MESH | Leukemia, Myeloid, Acute* / drug therapy | - |
dc.subject.MESH | Leukemia, Myeloid, Acute* / genetics | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Vascular Endothelial Growth Factor C / therapeutic use | - |
dc.subject.MESH | Vascular Endothelial Growth Factor Receptor-3 / therapeutic use | - |
dc.title | FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | BioMedical Science Institute (의생명과학부) | - |
dc.contributor.googleauthor | Ji Yoon Lee | - |
dc.contributor.googleauthor | Sung-Eun Lee | - |
dc.contributor.googleauthor | A-Reum Han | - |
dc.contributor.googleauthor | Jongeun Lee | - |
dc.contributor.googleauthor | Young-Sup Yoon | - |
dc.contributor.googleauthor | Hee-Je Kim | - |
dc.identifier.doi | 10.3324/haematol.2022.282472 | - |
dc.contributor.localId | A02579 | - |
dc.relation.journalcode | J00959 | - |
dc.identifier.eissn | 1592-8721 | - |
dc.identifier.pmid | 37317880 | - |
dc.contributor.alternativeName | Yoon, Young Sup | - |
dc.contributor.affiliatedAuthor | 윤영섭 | - |
dc.citation.volume | 108 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2933 | - |
dc.citation.endPage | 2945 | - |
dc.identifier.bibliographicCitation | HAEMATOLOGICA, Vol.108(11) : 2933-2945, 2023-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.